Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-04-22-Speech-2-945"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20080422.46.2-945"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
I voted in favour of discharge for the Director of the European Medicines Agency in respect of the implementation of its budget for the financial year 2006 on the basis of the report by my Austrian colleague Mr Hans-Peter Martin, which recommends to Parliament to give discharge. The discharge procedure should be simplified and streamlined for the decentralised agencies, which are growing in number
(from 8 in 2000, to 20 in 2006) and represent a total budget of around EUR 1 billion. I support the request for the Commission to present a study every five years on the added value of each agency and not to hesitate to close an agency if the analysis concludes that it is not useful. The internal audit procedures of the agencies also need urgent improvement and I support the possibility of having a common disciplinary board for all the agencies. I cannot understand the concerns of the board of the European Medicines Agency that the new tasks being allocated to it are not sufficiently funded. Indeed, the Agency’s financial situation appears to be flourishing, with a low level of use of funds (less than 60%) and considerable accounting surpluses associated with accumulations, and at the same time a subsidy from the Community and fees paid by the undertakings to maintain Community marketing authorisations for medicines (in other words revenue of EUR 119 million in 2006 plus a Community subsidy of EUR 31 million)."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples